Cakmak, Ayse IdilAkova, YoncaYildirim, Nilgun2024-09-182024-09-1820230927-39481744-5078https://doi.org/10.1080/09273948.2022.2091615https://hdl.handle.net/20.500.12483/7841Purpose To describe the management and outcome of two extremely rare and painful cases of Mooren's ulcer, an idiopathic peripheral autoimmune-associated ulcerative corneal disease. Methods Case report with literature review on the management of ocular inflammation in Mooren's ulcer. Results A 47-year-old female and a 76-year-old female presented with progressive bilateral Mooren's ulcer that were refractory to conventional immunosuppressive therapy. Following treatment with infliximab, an anti-tumor necrosis factor alpha, a significant improvement in disease progression was observed, with no corneal thinning or perforation at follow-ups. Conclusion This case report highlights how infliximab can be effective in cases with Mooren's ulcer refractory to conventional therapies.eninfo:eu-repo/semantics/closedAccessAnti-tumor necrosis factor alphaimmunosuppresioninfliximabMooren's ulcerperipheral ulcerative keratititsArticle31468268810.1080/09273948.2022.2091615358302402-s2.0-85134032514Q1WOS:000824358100001Q2